# A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

> **NCT03988920** · PHASE4 · COMPLETED · sponsor: **Ardelyx** · enrollment: 172 (actual)

## Conditions studied

- Hyperphosphatemia
- End Stage Renal Disease

## Interventions

- **DRUG:** Tenapanor
- **DRUG:** Sevelamer Carbonate

## Key facts

- **NCT ID:** NCT03988920
- **Lead sponsor:** Ardelyx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-15
- **Primary completion:** 2021-06-26
- **Final completion:** 2021-07-31
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2023-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03988920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03988920, "A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03988920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*